N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Biomarkers blood MeSH
- Cardiovascular Diseases blood mortality MeSH
- Middle Aged MeSH
- Humans MeSH
- Natriuretic Peptide, Brain blood MeSH
- Peptide Fragments blood MeSH
- Predictive Value of Tests * MeSH
- Prognosis MeSH
- Heart Failure * MeSH
- Health Surveys MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Biomarkers MeSH
- Natriuretic Peptide, Brain MeSH
- Peptide Fragments MeSH
- pro-brain natriuretic peptide (1-76) MeSH Browser
Brain natriuretic peptide (BNP) and its inactive N-terminal fragment (NT-proBNP) are strong prognostic markers in patients with manifest heart failure and acute coronary syndromes. We aimed to establish the association between NT-proBNP and all-cause mortality in patients with stable chronic coronary heart disease. Three-hundred-eighty-five patients, 6-24 months after acute coronary syndrome or coronary revascularisation, but without history or symptoms of chronic heart failure, were included into the cohort study. The NT-proBNP was measured at baseline and all-cause mortality was ascertained after more than 6 years of follow-up. Patients with NT-proBNP above 862 pmol/l (i.e. in top quintile) showed significantly higher mortality rates, than patients with lower NT-proBNP; the adjusted odds ratio (and 95% confidence intervals) for all-cause death was in patients with NT-proBNP >862 pmol/l 3.26 (1.40-7.62). In conclusion, the asymptomatic elevation of NT-proBNP provides prognostic information also in stable coronary patients not yet manifesting any symptoms of heart failure.
See more in PubMed
Eur Heart J. 2003 Oct;24(19):1735-43 PubMed
Circulation. 2002 Dec 3;106(23):2913-8 PubMed
N Engl J Med. 2005 Feb 17;352(7):666-75 PubMed
Eur J Cardiovasc Prev Rehabil. 2003 Aug;10(4):289-95 PubMed
Circulation. 2003 Jul 22;108(3):275-81 PubMed
Eur Heart J. 2001 Apr;22(7):554-72 PubMed
Circulation. 2006 Jul 18;114(3):201-8 PubMed
N Engl J Med. 2004 Feb 12;350(7):655-63 PubMed
Eur J Heart Fail. 2004 Mar 15;6(3):257-60 PubMed
FASEB J. 2003 Jun;17(9):1105-7 PubMed
Circulation. 2004 Sep 28;110(13):1780-6 PubMed
Clin Chem. 2003 Jun;49(6 Pt 1):976-9 PubMed
Heart. 2004 Mar;90(3):297-303 PubMed
Lancet. 2004 Sep 11-17;364(9438):937-52 PubMed
J Card Fail. 2009 Mar;15(2):101-7 PubMed
J Am Coll Cardiol. 2001 Jun 1;37(7):1781-7 PubMed
N Engl J Med. 1998 Jul 30;339(5):321-8 PubMed
N Engl J Med. 2001 Oct 4;345(14):1014-21 PubMed
JAMA. 2006 Jan 11;295(2):180-9 PubMed
